

National Stock Exchange of India

Circular

| Department: Listing | |
|--------------------------------|------------------------|
| Download Ref No: NSE/CML/55163 | Date: January 10, 2023 |
| Circular Ref. No: 0032/2023 | |

To All Members,

Sub: Suspension of trading in securities

Pursuant to the provisions of SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 with respect to Standard Operating Procedure (SOP) for suspension and revocation of trading of shares of listed entities for non-compliance with certain regulations of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ("Listing Regulations"), it is hereby informed that the following Company have not complied with requirements of Regulation 31 (i.e. Submission of Shareholding Pattern) of the Listing Regulations for two consecutive quarters' i.e. June 30, 2022 and September 30, 2022. Hence, the trading in securities of below named Company shall be suspended w.e.f. February 10, 2023. Details are as under:

| Sr. No. | Symbol | Name of Company |
|---------|--------|----------------------------------|
| 1 | PDPL | Parenteral Drugs (India) Limited |

Further if the above-mentioned Company do not comply as per the provisions of SOP Circular on or before February 07, 2023, then:

- Trading in securities of the above Company would be suspended w.e.f. February 10, 2023, and the suspension will continue till such time the Company comply with SOP Circular.
- After 15 days of suspension, trading in the securities of non-compliant Company would be allowed on Trade for Trade basis in (Z category) on the first trading day of every week for six months.

For and on behalf of
National Stock Exchange of India Limited

Ravi Shekhar Rai
Manager